MeSH tree: E05.318.372.250.250
Injecting nivolumab (Opdivo) directly into precancerous oral lesions led to a reduction in lesion size and allowed some patients to avoid surgery, according to research from a Phase I clinical trial presented at the American ...
1 hour ago
0
0
Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly concentrated at the top 20 ...
22 hours ago
0
1
The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D ...
Apr 20, 2026
0
2
Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according ...
Apr 20, 2026
0
3
The U.S. Food and Drug Administration (FDA) will soon review whether certain peptides should be allowed in customized medications made by compounding pharmacies.
Apr 17, 2026
0
3
A large international study has found that asundexian, an investigational anti-clotting medication, reduces the risk of a stroke in people who recently experienced a stroke or transient ischemic attack (TIA) caused by a clot ...
Apr 15, 2026
0
75
Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis. But a new drug developed at Northwestern University may soon help patients live ...
Apr 14, 2026
0
23
A clinical trial led by University of Auckland researchers found that high-intensity therapy for patients begun within two weeks of a stroke did not improve hand and arm recovery beyond standard care. Targeting new treatments ...
Mar 26, 2026
0
2
An experimental vaccine for Lyme disease is broadly effective, pharmaceutical companies Pfizer and Valneva announced Monday; however, the latter firm's shares fell because the clinical trial did not reach its main goal.
Mar 23, 2026
0
7
Findings from two early clinical studies suggest a new dual-action antimalarial drug candidate is well tolerated in humans. The first-in-class clinical candidate, MK7602, is being developed by WEHI and global biopharmaceutical ...
Mar 19, 2026
0
19
